Alimta And Carboplatin Side Effects

Low white blood cells neutropenia 63 nausea vomiting 57 increased bleeding risk low platelets.

Alimta and carboplatin side effects. Thrombocytopenia 51 fatigue 44 liver injury 22 anemia low red blood cells 21. Some side effects may occur that usually do not need medical attention. If experienced these tend to have a severe expression. Bloody urine or bloody stools decreased frequency or amount of urine fainting or loss of consciousness fast or irregular breathing increased blood pressure increased thirst itching skin rash loss of appetite nausea swelling of the eyes eyelids face fingers or lower legs tightness in the chest.

Nosebleeds bleeding gums tiny red or purple spots on the skin that may look like a rash. Feeling breathless can be. Fatigue 64 nausea 58 low red blood cells anemia 32. A skin rash over areas of previous radiotherapy weight gain.

If you notice any other effects check with your healthcare professional. These side effects may go away during treatment as your body adjusts to the medicine. This medicine may cause a temporary loss of hair in some people. Some side effects of carboplatin may occur that usually do not need medical attention.

Stomach cramps tenderness or pain. A build up of fluid swelling in your arms hands ankles legs face and other parts of the body blood clots that are life threatening. Signs are pain swelling and redness where the clot is. After treatment with carboplatin has ended normal hair growth should return.

In clinical studies the most commonly reported carboplatin pemetrexed side effects are shown here. Alimta vial side effects by likelihood and severity common side effects. In clinical studies the most commonly reported pembrolizumab carboplatin pemetrexed side effects are shown here. Other side effects not listed may also occur in some patients.

Side effects not requiring immediate medical attention. Also your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. The following adverse reactions are discussed in greater detail in other sections of the labeling.